Antiamnesic activity of the nicotinic agonist DBO-83 in mice

✍ Scribed by Carla Ghelardini; Nicoletta Galeotti; Francesco Giuliani; Daniela Barlocco; Alessandro Bartolini

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 171 KB
• Volume: 45
• Category: Article
• ISSN: 0272-4391
• DOI: 10.1002/(sici)1098-2299(199810)45:2<45::aid-ddr1>3.0.co;2-q

✦ Synopsis

The effect of administration of DBO-83 on memory processes was evaluated in the mouse passive avoidance test. DBO-83 (1-5 mgkg -1 ip) prevented amnesia induced by scopolamine (1.5 mgkg -1 ip), mecamylamine (20 mgkg -1 ip) and dihydro-β-erythroidine (10 µg per mouse i.c.v.). In the same experimental conditions, DBO-83 (10 mgkg -1 ip) also prevented baclofen (2 mgkg -1 ip), clonidine (0.125 mgkg -1 ip) and diphenhydramine (20 mgkg -1 ip) amnesia in mice. The antiamnesic effect of DBO-83 was comparable to that exerted by nicotine (2 mgkg -1 ip), physostigmine (0.2 mgkg -1 ip), and the nootropic drug, piracetam (30 mgkg -1 ip). In the antiamnesic dose-range, DBO-83 did not impair mouse motor coordination and spontaneous motility, as revealed, respectively, by the Animex apparatus and rotarod test. These results demonstrated the ability of DBO-83 to modulate memory functions and suggest that DBO-83 could be useful in the treatment of cognitive deficits.